Gilead Sciences (NASDAQ:GILD) CEO Sells $1,398,900.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total value of $1,398,900.00. Following the sale, the chief executive officer owned 556,698 shares in the company, valued at approximately $77,876,483.22. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00.

Gilead Sciences Stock Performance

GILD stock traded down $0.17 during midday trading on Thursday, reaching $139.55. 7,147,792 shares of the company’s stock traded hands, compared to its average volume of 7,661,948. The stock’s 50-day moving average is $124.76 and its 200 day moving average is $119.24. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $141.71. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a market cap of $173.14 billion, a P/E ratio of 21.64, a PEG ratio of 0.74 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 earnings per share. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Institutional Trading of Gilead Sciences

Several large investors have recently bought and sold shares of the business. Csenge Advisory Group lifted its position in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd increased its stake in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares during the period. TriaGen Wealth Management LLC acquired a new position in Gilead Sciences in the 3rd quarter worth $1,274,000. iA Global Asset Management Inc. boosted its position in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after buying an additional 23,046 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. TD Cowen raised their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Morgan Stanley dropped their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. Citigroup increased their price target on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.56.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.